Besse B et al. Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). ESMO 2022;Abstract 1170P.
Drilon A et al. Targeting RET-driven cancers: Lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 2018;15(3):150. Abstract
Drilon A et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2020;383(9):813-24. Abstract
Gainor JF et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021;22(7):959-69. Abstract
Griesinger F et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial. Ann Oncol 2022;[Online ahead of print]. Abstract
Kalchiem-Dekel O et al. Brief report: Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy. J Thorac Oncol 2022;17(9):1130-6. Abstract
Kolakowski GR et al. Pre-clinical characterization of potent and selective next-generation RET inhibitors. AACR 2021;Abstract 1464.
Lin JJ et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol 2020;31(12):1725-33. Abstract
Lin JJ, Gainor JF. Selective targeting of RET fusions in lung cancer. J Clin Oncol 2022;[Online ahead of print]. Abstract
Rosen EY et al. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nat Commun 2022;13(1):1450. Abstract
Rosen EY et al. Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res 2020;27(1):34-42. Abstract
Solomon BJ et al. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncol 2021;17(7):763-73. Abstract
Subbiah V et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discovery 2018;8(7):836-49. Abstract
Subbiah V et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 2018;29(8):1869-76. Abstract